aTyr Pharma Yönetim
Yönetim kriter kontrolleri 4/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Sanjay Shukla
İcra Kurulu Başkanı
US$1.3m
Toplam tazminat
CEO maaş yüzdesi | 43.2% |
CEO görev süresi | 7yrs |
CEO sahipliği | 0.2% |
Yönetim ortalama görev süresi | 5.9yrs |
Yönetim Kurulu ortalama görev süresi | 15.1yrs |
Son yönetim güncellemeleri
Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$58m |
Mar 31 2024 | n/a | n/a | -US$54m |
Dec 31 2023 | US$1m | US$561k | -US$50m |
Sep 30 2023 | n/a | n/a | -US$43m |
Jun 30 2023 | n/a | n/a | -US$45m |
Mar 31 2023 | n/a | n/a | -US$45m |
Dec 31 2022 | US$2m | US$561k | -US$45m |
Sep 30 2022 | n/a | n/a | -US$46m |
Jun 30 2022 | n/a | n/a | -US$41m |
Mar 31 2022 | n/a | n/a | -US$39m |
Dec 31 2021 | US$2m | US$510k | -US$34m |
Sep 30 2021 | n/a | n/a | -US$30m |
Jun 30 2021 | n/a | n/a | -US$29m |
Mar 31 2021 | n/a | n/a | -US$25m |
Dec 31 2020 | US$1m | US$470k | -US$16m |
Sep 30 2020 | n/a | n/a | -US$17m |
Jun 30 2020 | n/a | n/a | -US$16m |
Mar 31 2020 | n/a | n/a | -US$16m |
Dec 31 2019 | US$664k | US$450k | -US$24m |
Sep 30 2019 | n/a | n/a | -US$24m |
Jun 30 2019 | n/a | n/a | -US$25m |
Mar 31 2019 | n/a | n/a | -US$30m |
Dec 31 2018 | US$1m | US$450k | -US$35m |
Sep 30 2018 | n/a | n/a | -US$40m |
Jun 30 2018 | n/a | n/a | -US$44m |
Mar 31 2018 | n/a | n/a | -US$45m |
Dec 31 2017 | US$2m | US$403k | -US$48m |
Tazminat ve Piyasa: Sanjay 'ın toplam tazminatı ($USD 1.30M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.47M ).
Tazminat ve Kazançlar: Sanjay 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Sanjay Shukla (52 yo)
7yrs
Görev süresi
US$1,300,525
Tazminat
Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 7yrs | US$1.30m | 0.18% $ 443.8k | |
Chief Financial Officer | 6.3yrs | US$677.84k | 0.027% $ 67.7k | |
General Counsel & Corporate Secretary | 10.1yrs | US$651.28k | 0.029% $ 72.4k | |
Founder | no data | Veri yok | Veri yok | |
Vice President of Technical Operations | less than a year | Veri yok | Veri yok | |
Director of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok | |
Vice President of Corporate Development | 4.8yrs | Veri yok | Veri yok | |
VP of Human Resource | 2.9yrs | Veri yok | Veri yok | |
Vice President of Research | no data | Veri yok | Veri yok | |
Executive Director of Biologics Development & Manufacturing | no data | Veri yok | Veri yok | |
Scientific Consultant | 5.9yrs | US$717.31k | Veri yok |
5.9yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim: ATYR 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 7yrs | US$1.30m | 0.18% $ 443.8k | |
Independent Director | 19.2yrs | US$120.84k | 0.026% $ 64.3k | |
Independent Director | 19.2yrs | US$61.20k | 1.45% $ 3.6m | |
Member of Scientific Advisory Board | 15.1yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 15.3yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Independent Chairman of the Board | 7.6yrs | US$92.20k | 0.074% $ 182.0k | |
Member of Scientific Advisory Board | 15.2yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Independent Director | 5.3yrs | US$68.88k | 0.0079% $ 19.5k |
15.1yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ATYR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15.1 yıldır).